Edwards Lifesciences Corp (EW)vsInfuSystems Holdings Inc (INFU)
EW
Edwards Lifesciences Corp
$85.96
-1.70%
HEALTHCARE · Cap: $49.01B
INFU
InfuSystems Holdings Inc
$9.03
+1.69%
HEALTHCARE · Cap: $186.48M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 4326% more annual revenue ($6.30B vs $142.40M). EW leads profitability with a 17.4% profit margin vs 5.5%. INFU appears more attractively valued with a PEG of 1.73. EW earns a higher WallStSmart Score of 61/100 (C+).
EW
Buy61
out of 100
Grade: C+
INFU
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.7%
Fair Value
$253.29
Current Price
$85.96
$167.33 discount
Margin of Safety
+26.5%
Fair Value
$10.36
Current Price
$9.03
$1.33 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
Earnings expanding 123.9% YoY
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Expensive relative to growth rate
Grey zone — moderate risk
Smaller company, higher risk/reward
5.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bull Case : INFU
The strongest argument for INFU centers on EPS Growth.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Bear Case : INFU
The primary concerns for INFU are PEG Ratio, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
EW profiles as a growth stock while INFU is a value play — different risk/reward profiles.
INFU carries more volatility with a beta of 1.42 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
INFU generates stronger free cash flow (-867,000), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 51/100), backed by strong 17.4% margins and 16.7% revenue growth. INFU offers better value entry with a 26.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →InfuSystems Holdings Inc
HEALTHCARE · MEDICAL DEVICES · USA
InfuSystem Holdings, Inc., provides infusion pumps and related products and services in the United States and Canada. The company is headquartered in Rochester Hills, Michigan.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?